Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 2361-2370 Newer>

The Motley Fool June 17, 2004 Brian Gorman	Genentech's Unique Drug Genentech and Biogen Idec's Phase II trial demonstrating Rituxan's effectiveness in treating moderate-to-severe rheumatoid arthritis was enshrined in the prestigious pages of the New England Journal of Medicine, adding heft to the study's results.
The Motley Fool June 17, 2004 Rich Smith	Outsourcing to the Heartland If you can save the same money here as there, and avoid public criticism at the same time, it just makes sense to outsource locally. Investors in the companies that realize they don't need to go abroad to save money will be the ones to reap the benefits.
The Motley Fool June 17, 2004 Dave Marino-Nachison	Jones, Maxwell Negotiate Hostile and/or unsolicited buyout offers are invariably exciting to watch, but can be nerve-racking if you've got something invested.
The Motley Fool June 17, 2004 Mike Cianciolo	Callaway Slices Expectations Shares of Big Bertha creator Callaway Golf sank by more than 20% yesterday after the company reported weakening sales trends.
The Motley Fool June 17, 2004 Seth Jayson	P&G Patches Up Sex Life? Proctor & Gamble announced that a second phase 3 clinical trial had demonstrated the safety and efficacy of its testosterone patch, to be called Intrinsa, for treating sexual dysfunction in women.
The Motley Fool June 17, 2004 Charly Travers	No Heartburn for Santarus As a small company, Santarus is definitely going to have its hands full marketing the new heartburn drug Rapinex against some of the biotech giants.
The Motley Fool June 17, 2004 Selena Maranjian	Fools Don't Rush In Be skeptical when you see lists of recommended stocks, and think for yourself. Some companies will perform well, but many won't. Do some research on your own, and find the firms that suit you best.
The Motley Fool June 17, 2004 Tom Taulli	No Exultation Over HR Deal Yesterday, human resources outsourcing and consulting firm Hewitt Associates announced it was purchasing Exult in a stock-for-stock deal. Shareholders dumped on the deal. But a Hewitt-Exult combination makes a lot of sense.
The Motley Fool June 17, 2004 Rick Munarriz	Home Sweet KB Home Homebuilder KB Home shines a light on the housing sector.
InternetNews June 16, 2004 Paul Shread	Technical Analysis: Stocks Stall The PPI in the morning could help - or hurt.
<Older 2361-2370 Newer> Return to current articles.